Compare

Cabaletta Bio, Inc. vs Aura Biosciences, Inc. vs SAB Biotherapeutics, Inc. vs Compugen Ltd

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Cabaletta Bio, Inc. CABA	Aura Biosciences, Inc. AURA	SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue)	Compugen Ltd CGEN
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	$72.76M
Revenue growth (YoY)	n/a	n/a	n/a	+161.1%
Gross margin	n/a	n/a	n/a	87.3%
Operating margin	n/a	n/a	n/a	43.1%
Net margin	n/a	n/a	n/a	48.6%
Net income	-$167.86M	-$106.19M	$13.27M	$35.34M
EPS (Diluted)	-$2.10	-$1.76	-$0.79	$0.38
Operating cash flow	-$131.08M	-$84.74M	-$44.78M	$31.63M
Free cash flow	-$132.31M	-$85.19M	-$45.71M	$31.33M
Cash & equivalents	$82.98M	$59.52M	$10.50M	$90.60M
Total assets	$165.08M	$169.43M	$172.81M	$156.57M
Total liabilities	$53.03M	$32.52M	$21.32M	n/a
Shareholders' equity	$112.05M	$136.91M	$151.49M	$102.73M
Return on year-end equity	-149.8%	-77.6%	8.8%	34.4%
Shares outstanding	100.48M	63.59M	47.61M	94.55M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Cabaletta Bio, Inc.	Aura Biosciences, Inc.	SAB Biotherapeutics, Inc.	Compugen Ltd
Latest	n/a	n/a	n/a	$72.76M Ended 2025-12-31
1 year earlier	n/a	n/a	n/a	$27.86M Ended 2024-12-31
2 years earlier	n/a	n/a	n/a	$33.46M Ended 2023-12-31
3 years earlier	n/a	n/a	n/a	$7.50M Ended 2022-12-31
4 years earlier	n/a	n/a	n/a	$6.00M Ended 2021-12-31